Celgene Corp. (NASDAQ:CELG)’s stock had its “outperform” rating reaffirmed by equities researchers at Cowen and Company in a research report issued on Monday. The stock had a trading volume of 4,033,803 shares. BMO Capital Markets reaffirmed an “outperform” rating and issued a $141.00 price target on shares of Celgene Corp.in a report on Tuesday, August 23rd.
Advertisement
Earnings Roundup: In the last fiscal quarter alone, Celgene Corporation generated almost $2.75B in sales and net income of $1.44/share. The stock tapped a 52-week high of US$28.71 while the 12-month Consensus Price Target is US$31.39. Celgene Corp. has a 52 week low of $93.05 and a 52 week high of $128.39. Leerink Swann reiterated a “market perform” rating and set a $135.00 target price on shares of Celgene Corp.in a report on Monday. The stock’s 50-day moving average is $110.83 and its 200-day moving average is $104.82. (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 28th. For the reporting quarter, equity analysts expect the stock to deliver $1.48 in earnings per share (EPS). For the prior quarter revenue for the stock hit $2.51B, with EPS at $1.32.
Company latest quarter ended on 30 Jun 2016, company announced earnings of $1.44. The company’s revenue for the quarter was up 20.9% compared to the same quarter a year ago. Also, insider Robert J. Hugin sold 100,000 shares of the stock in a transaction on Thursday, July 28th. Celgene Corporation makes up approx 0.02% of Beck Mack Oliver’s portfolio.Burt Wealth Advisors reduced its stake in CELG by selling 20 shares or 4.44% in the most recent quarter. Following the completion of the sale, the insider now owns 1,122,201 shares of the company’s stock, valued at $112,399,652.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. CELG Director Haley John K also sold 3,400 shares, at a stock price of $30.96. 5 rated the company as a “Hold”. The disclosure for this sale can be found here. Insiders are expected to have better knowledge about the health and prospects of their company, which is why insiders’ move deserves attention. Jolley Asset Management LLC now owns 1,215 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 450 shares during the period. Meristem LLP boosted its position in shares of Celgene Corp.by 1.7% in the second quarter. Janney Montgomery Scott LLC now owns 119,092 shares of the biopharmaceutical company’s stock worth $14,262,000 after buying an additional 13,432 shares during the last quarter. Opera Trading Capital now owns 1,563 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 900 shares in the last quarter. Finally, Signaturefd LLC boosted its position in shares of Celgene Corp.by 1.2% in the second quarter. Glenview State Bank Trust DEPT. now owns 12,400 shares of the biopharmaceutical company’s stock worth $1,223,000 after buying an additional 2,225 shares during the period. Institutional investors and hedge funds own 77.81% of the company’s stock.
Net money flow in Celgene Corporation (CELG) was negative ($33.67 million) and the inflow of money on uptick was $121.59 million, whereas, the outflow of money on downticks amounted to $155.26 million on Monday.
Advertisement
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
